Targets — browse / sort / filter (view)
Data license: CC BY 4.0 · Data source: apt-scout automated curation pipeline (E. Dohi, NCNP) — values harvested from public databases; raw source stored per target
- id
- UniProt accession (human). Links to uniprot.org.
- gene_symbol
- Gene symbol (e.g. ITGB3).
- protein_name
- Protein name (UniProt).
- tier
- Tier 1 = PDB-anchored; Tier 1.5 = AlphaFold-confident.
- has_structure
- 1 if the target protein has a reported experimental 3D structure (PDB). This is the CORE requirement the aptamer-Kd layer is built around — filter to 1 for the structure-backed set.
- evidence_priority
- DETERMINISTIC, reproducible prioritisation (0-1) computed at build time from real harvested columns: 0.35*experimental-structure(PDB=1 / AlphaFold-only=0.3) + 0.30*Open-Targets-top-disease-score + 0.20*PREDICTED-surface-accessibility(A_surface=1) + 0.15*EV-detection(EV-Map). A transparent ranking AID, not a validation; the surface/EV terms are PREDICTIONS/DETECTIONS, not measured EV-surface exposure. Recomputable exactly from this DB.
- has_activation_state_pdb_pair
- 1 if a curated ACTIVE/INACTIVE PDB pair exists (only 11 targets).
- in_cev_map
- Detected in the EV-Map plasma-EV dataset (Rai & Greening 2025, Nat Cell Biol, 10.1038/s41556-025-01795-7) = 3,422 apt-scout targets (broad detected proteome). The EV-Map CONSERVED EV proteome is 182 proteins (42 non-EV); apt-scout matches 104 of these conserved EV-hallmark proteins as targets by gene (the other 78 are not apt-scout targets). Use the ev_hallmark_targets query for that subset. IMPORTANT: EV-Map detection means the protein is EV CARGO (present in the vesicle) — it does NOT mean surface-exposed. Rai & Greening 2025 run a separate membrane-impermeant biotinylation assay giving a 151-protein SURFACEOME, and show the conserved SDCBP/syntenin is luminal (not surface-accessible). For genuine EV-surface accessibility use that 151-protein set, not EV-Map presence.
- has_known_aptamer
- 1 if PubMed '(gene) AND (aptamer OR SELEX)' returned any hit (KEYWORD co-mention, includes false positives — NOT a verified aptamer). For verified aptamers with Kd, see the Binding-affinities (v_kd) layer.
- opentargets_top_disease_score
- Open Targets association score (0-1).
- aptamer_count_pubmed
- Number of PubMed hits for (this protein) AND (aptamer OR SELEX). Keyword co-occurrence — verify each (many co-mention without a real aptamer).
- aptamer_pmids
- The actual PubMed IDs behind the aptamer evidence — click each to read the paper. This is the source of the 'has aptamer' claim.
- surface_class
- PREDICTED membrane topology (HPA-derived, not a measurement): A_surface = integral/ecto cell-surface (predicted EV-surface accessible); A2_pm_peripheral = plasma-membrane cytoplasmic-leaflet (SRC/LYN/RHOA, predicted not reachable); A_assoc = secreted/corona; B_cargo = luminal cargo; unknown = no HPA localization. Lipid asymmetry can partially flip (PS via scramblase); confirm by protease-protection / intact-EV surface labelling. See v_surface_targets.
454 rows where has_cryoEM = 0, has_known_aptamer = 1 and in_cev_map = 0 sorted by evidence_priority descending
This data as json, CSV (advanced)
surface_class 5
- B_cargo 243
- A_assoc 92
- A_surface 84
- A2_pm_peripheral 30
- unknown 5
in_cev_map 1
- - · 454 ✖
has_known_aptamer 1
- 1 · 454 ✖
has_cryoEM 1
- - · 454 ✖
has_activation_state_pdb_pair 1
- 0 454
| id | gene_symbol | protein_name | tier | evidence_priority ▲ | has_structure | surface_class | pdb_count_total | alphafold_mean_pLDDT | has_cryoEM | has_activation_state_pdb_pair | activation_state_pdb_active | activation_state_pdb_inactive | has_known_aptamer | aptamer_count_pubmed | aptamer_pmids | in_cev_map | opentargets_top_disease_name | opentargets_top_disease_score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P07333 | CSF1R | Macrophage colony-stimulating factor 1 receptor | Tier 1 | 0.802 | 1 | A_surface | 26 | 77.81 | 0 | 0 | 1 | 1 | 29277631 | 0 | leukoencephalopathy, diffuse hereditary, with spheroids 1 | 0.8391971566583056 | ||
| P42262 | GRIA2 | Glutamate receptor 2 | Tier 1 | 0.8 | 1 | A_surface | 16 | 84.94 | 0 | 0 | 1 | 4 | 28325839, 19417060, 17929944, 17024188 | 0 | neurodevelopmental disorder with language impairment and behavioral abnormalities | 0.8328652004757138 | ||
| P10912 | GHR | Growth hormone receptor | Tier 1.5 | 0.799 | 1 | A_surface | 9 | 58.69 | 0 | 0 | 1 | 5 | 38811951, 38477735, 31603904 | 0 | Laron syndrome | 0.8304020079647765 | ||
| Q01974 | ROR2 | Tyrosine-protein kinase transmembrane receptor ROR2 | Tier 1 | 0.794 | 1 | A_surface | 6 | 68.31 | 0 | 0 | 1 | 2 | 41782379, 18673242 | 0 | autosomal recessive Robinow syndrome | 0.8145559265435566 | ||
| Q9UM73 | ALK | ALK tyrosine kinase receptor | Tier 1 | 0.791 | 1 | A_surface | 79 | 68.19 | 0 | 0 | 1 | 6 | 40347134, 38604287, 32218299, 29205808, 24116381, 21281497 | 0 | neuroblastoma | 0.8016889264946979 | ||
| Q4KMG0 | CDON | Cell adhesion molecule-related/down-regulated by oncogenes | Tier 1 | 0.79 | 1 | A_surface | 3 | 62.03 | 0 | 0 | 1 | 3 | 36333824, 24629635, 18698484 | 0 | holoprosencephaly | 0.800378039564866 | ||
| P16410 | CTLA4 | Cytotoxic T-lymphocyte protein 4 | Tier 1.5 | 0.787 | 1 | A_surface | 22 | 80.12 | 0 | 0 | 1 | 26 | 41907643, 40972397, 40870970, 40811947, 40536609, 39417693, 38473398, 38158454, 36966395, 36831533, 36603108, 36015348, 33970170, 32929022, 32840510, 32280743, 32024070, 31405808, 28918052, 28082399, 26030229, 25565435, 24892807, 23460536, 23460531, 14612549 | 0 | autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency | 0.7906408646569979 | ||
| P22223 | CDH3 | Cadherin-3 | Tier 1 | 0.786 | 1 | A_surface | 19 | 76.75 | 0 | 0 | 1 | 1 | 41304780 | 0 | EEM syndrome | 0.7851776755128059 | ||
| Q96MS0 | ROBO3 | Roundabout homolog 3 | Tier 1.5 | 0.784 | 1 | A_surface | 3 | 63.69 | 0 | 0 | 1 | 2 | 32369590 | 0 | horizontal gaze palsy with progressive scoliosis | 0.7813306356858872 | ||
| P26678 | PLN | Phospholamban | Tier 1 | 0.775 | 1 | A_surface | 7 | 81.88 | 0 | 0 | 1 | 9 | 39536855, 32382487, 30777430, 25240642, 21848510, 19158349 | 0 | hypertrophic cardiomyopathy | 0.750557685745381 | ||
| Q9HBE5 | IL21R | Interleukin-21 receptor | Tier 1 | 0.775 | 1 | A_surface | 6 | 64.12 | 0 | 0 | 1 | 2 | 30800133, 29244152 | 0 | Cryptosporidiosis - chronic cholangitis - liver disease | 0.7501392499286187 | ||
| Q9Y6Q6 | TNFRSF11A | Tumor necrosis factor receptor superfamily member 11A | Tier 1 | 0.775 | 1 | A_surface | 1 | 58.91 | 0 | 0 | 1 | 1 | 15562003 | 0 | Osteopetrosis - hypogammaglobulinemia | 0.7487328542164448 | ||
| P40126 | DCT | L-dopachrome tautomerase | Tier 1.5 | 0.774 | 1 | A_surface | 1 | 89.12 | 0 | 0 | 1 | 1 | 27245069 | 0 | oculocutaneous albinism type 8 | 0.7468868816172217 | ||
| Q9NR97 | TLR8 | Toll-like receptor 8 | Tier 1 | 0.771 | 1 | A_surface | 39 | 86.12 | 0 | 0 | 1 | 4 | 40085160, 39956743 | 0 | immunodeficiency 98 with autoinflammation, X-linked | 0.7360623201088097 | ||
| P26842 | CD27 | CD27 antigen | Tier 1 | 0.763 | 1 | A_surface | 5 | 71.69 | 0 | 0 | 1 | 3 | 39841045, 30609550, 26320067 | 0 | lymphoproliferative syndrome 2 | 0.7084378623696481 | ||
| P15941 | MUC1 | Mucin-1 | Tier 1 | 0.761 | 1 | A_surface | 23 | 47.41 | 0 | 0 | 1 | 686 | 42025056, 41988862, 41954302, 41771296, 41744704, 41744190, 41657320, 41627316, 41621292, 41582516, 41535857, 41471303, 41362016, 41352919, 41346179, 41330302, 41243570, 41205458, 41185018, 41101154, 41047832, 41027169, 40682599, 40665615, 40627939, 40607530, 40590839, 40578633, 40568899, 40556592, 40504676, 40500890, 40499867, 40479828, 40432219, 40422041, 40360093, 40286646, 40274149, 40158809, 40119836, 39978149, 39910821, 39705316, 39679901, 39626346, 39579679, 39566700, 39552005, 39550818, 41997681, 41247195, 40813258, 39454542, 39454415, 39440615, 39421884, 39406784, 39256285, 39243449, 39154820, 39142532, 39136402, 39119745, 39118454, 38923850, 38912896 | 0 | tubulointerstitial kidney disease, autosomal dominant, 2 | 0.7040398435219726 | ||
| P48023 | FASLG | Tumor necrosis factor ligand superfamily member 6 | Tier 1.5 | 0.76 | 1 | A_surface | 3 | 80.19 | 0 | 0 | 1 | 1 | 16581027 | 0 | autoimmune lymphoproliferative syndrome type 1 | 0.6984292519156657 | ||
| O14788 | TNFSF11 | Tumor necrosis factor ligand superfamily member 11 | Tier 1 | 0.759 | 1 | A_surface | 2 | 79.19 | 0 | 0 | 1 | 2 | 15562003, 41226313 | 0 | osteoporosis | 0.6957850224892792 | ||
| P32970 | CD70 | CD70 antigen | Tier 1.5 | 0.75 | 1 | A_surface | 1 | 83.19 | 0 | 0 | 1 | 1 | 30609550 | 0 | severe combined immunodeficiency due to CD70 deficiency | 0.6651491980619259 | ||
| Q9HCK4 | ROBO2 | Roundabout homolog 2 | Tier 1.5 | 0.744 | 1 | A_surface | 6 | 67.38 | 0 | 0 | 1 | 2 | 40616090, 31640794 | 0 | familial vesicoureteral reflux | 0.6460375744556555 | ||
| P48551 | IFNAR2 | Interferon alpha/beta receptor 2 | Tier 1 | 0.743 | 1 | A_surface | 9 | 64.44 | 0 | 0 | 1 | 1 | 35212764 | 0 | COVID-19 | 0.6417504201511338 | ||
| Q15116 | PDCD1 | Programmed cell death protein 1 | Tier 1 | 0.738 | 1 | A_surface | 37 | 74.12 | 0 | 0 | 1 | 27 | 41479885, 40811947, 40758411, 39562585, 37424077, 34156677, 33904236, 33896107, 33319876, 33155587, 32574155, 32429721, 31727249, 31434881, 28912094, 28288993, 41907643, 41125194, 38158454, 37944524, 36484532, 36015348, 34861397, 34386332 | 0 | melanoma | 0.6260691959208758 | ||
| Q9NR96 | TLR9 | Toll-like receptor 9 | Tier 1 | 0.736 | 1 | A_surface | 3 | 86.75 | 0 | 0 | 1 | 30 | 41617261, 40657739, 39841045, 39830661, 33896107, 32143069, 28594360, 26003847, 23046187, 22174879, 19325804, 18495099, 12828856, 37161583, 34730968, 30526333, 29450964, 17665991 | 0 | rheumatoid arthritis | 0.6213924969410908 | ||
| P19235 | EPOR | Erythropoietin receptor | Tier 1 | 0.735 | 1 | A_surface | 21 | 66.94 | 0 | 0 | 1 | 6 | 31904170, 31279934, 20142506, 41207063 | 0 | anemia (phenotype) | 0.6151472861334055 | ||
| Q8N126 | CADM3 | Cell adhesion molecule 3 | Tier 1.5 | 0.735 | 1 | A_surface | 1 | 84.38 | 0 | 0 | 1 | 2 | 39263947 | 0 | Charcot-Marie-Tooth disease, axonal, type 2FF | 0.6157861516342734 | ||
| P20138 | CD33 | Myeloid cell surface antigen CD33 | Tier 1 | 0.729 | 1 | A_surface | 9 | 77.44 | 0 | 0 | 1 | 12 | 41643149, 40224444, 40148126, 39778270, 39601387, 34202358, 30519686, 27514505, 22954922, 22344439, 21729522, 20144587 | 0 | acute myeloid leukemia | 0.5974217137912493 | ||
| P21709 | EPHA1 | Ephrin type-A receptor 1 | Tier 1.5 | 0.724 | 1 | A_surface | 4 | 80.38 | 0 | 0 | 1 | 4 | 35283197, 24629635, 41325160 | 0 | Alzheimer disease | 0.5784090512493305 | ||
| P31358 | CD52 | CAMPATH-1 antigen | Tier 1.5 | 0.723 | 1 | A_surface | 1 | 67.19 | 0 | 0 | 1 | 1 | 39865939 | 0 | chronic lymphocytic leukemia | 0.5770414699711784 | ||
| Q96D42 | HAVCR1 | Hepatitis A virus cellular receptor 1 | Tier 1 | 0.716 | 1 | A_surface | 2 | 65.81 | 0 | 0 | 1 | 7 | 41890985, 41709264, 41707424, 37533140 | 0 | dengue disease | 0.5546458763430171 | ||
| Q04609 | FOLH1 | Glutamate carboxypeptidase 2 | Tier 1 | 0.715 | 1 | A_surface | 88 | 93.81 | 0 | 0 | 1 | 47 | 41855944, 41683470, 41548790, 41478044, 41126016, 40684732, 39388218, 39187748, 38769597, 34341883, 33794195, 33061374, 33025277, 32721116, 32611993, 32525981, 32208602, 29313393, 28794625, 28746182, 27574424, 27456457, 27228412, 27077564, 26985893, 26472453, 26438155, 25938427, 25620467, 25620167, 25473281, 24954476, 24337602, 24321253, 23590171, 21980237, 21641946, 21555850, 21147500, 20550178, 20407731, 19701187, 19514954, 19488725, 18776550, 15520166, 12124337 | 0 | prostate cancer | 0.5500818985644047 | ||
| Q07011 | TNFRSF9 | Tumor necrosis factor receptor superfamily member 9 | Tier 1 | 0.707 | 1 | A_surface | 14 | 82.0 | 0 | 0 | 1 | 8 | 41574287, 26007661, 20201573, 28082399, 24938283, 18060045 | 0 | immunodeficiency 109 with lymphoproliferation | 0.5237187260560908 | ||
| O43653 | PSCA | Prostate stem cell antigen | Tier 1.5 | 0.706 | 1 | A_surface | 1 | 81.31 | 0 | 0 | 1 | 2 | 41911185 | 0 | duodenal ulcer | 0.5197329863180171 | ||
| P43489 | TNFRSF4 | Tumor necrosis factor receptor superfamily member 4 | Tier 1 | 0.705 | 1 | A_surface | 8 | 77.0 | 0 | 0 | 1 | 1 | 23113766 | 0 | combined immunodeficiency due to OX40 deficiency | 0.5161684039676777 | ||
| P15884 | TCF4 | Transcription factor 4 | Tier 1 | 0.705 | 1 | A_assoc | 5 | 51.12 | 0 | 0 | 1 | 4 | 36252203, 17909039, 41851110, 37805109 | 0 | Pitt-Hopkins syndrome | 0.8490531860867685 | ||
| P10747 | CD28 | T-cell-specific surface glycoprotein CD28 | Tier 1 | 0.703 | 1 | A_surface | 10 | 81.31 | 0 | 0 | 1 | 12 | 40702285, 40479828, 36979667, 36126113, 32584540, 32280743, 32024070, 26999456, 26992239, 26320067, 23756353, 10435754 | 0 | HIV infection | 0.5105949023227331 | ||
| Q9NPF0 | CD320 | CD320 antigen | Tier 1 | 0.7 | 1 | A_surface | 6 | 63.81 | 0 | 0 | 1 | 1 | 39493449 | 0 | Methylmalonic aciduria due to transcobalamin receptor defect | 0.49918945650121177 | ||
| P35590 | TIE1 | Tyrosine-protein kinase receptor Tie-1 | Tier 1.5 | 0.695 | 1 | A_surface | 1 | 80.81 | 0 | 0 | 1 | 1 | 35045701 | 0 | lymphatic malformation 11 | 0.4838261303064323 | ||
| P20062 | TCN2 | Transcobalamin-2 | Tier 1 | 0.694 | 1 | A_assoc | 11 | 91.5 | 0 | 0 | 1 | 3 | 41935727, 39493449 | 0 | transcobalamin II deficiency | 0.8116989428679681 | ||
| P45452 | MMP13 | Collagenase 3 | Tier 1 | 0.691 | 1 | A_assoc | 49 | 88.62 | 0 | 0 | 1 | 4 | 41754778, 40893365, 38471488, 38750696 | 0 | spondyloepimetaphyseal dysplasia, Missouri type | 0.8032079813035149 | ||
| P26951 | IL3RA | Interleukin-3 receptor subunit alpha | Tier 1 | 0.691 | 1 | A_surface | 4 | 85.25 | 0 | 0 | 1 | 3 | 40931580, 36171541, 31323275 | 0 | acute myeloid leukemia | 0.46904332714118013 | ||
| P31994 | FCGR2B | Low affinity immunoglobulin gamma Fc region receptor II-b | Tier 1.5 | 0.688 | 1 | A_surface | 5 | 78.44 | 0 | 0 | 1 | 1 | 38928037 | 0 | systemic lupus erythematosus | 0.460465747544726 | ||
| Q13253 | NOG | Noggin | Tier 1.5 | 0.685 | 1 | A_assoc | 2 | 86.06 | 0 | 0 | 1 | 2 | 38397086 | 0 | proximal symphalangism 1A | 0.7844136456463046 | ||
| Q96S42 | NODAL | Nodal homolog | Tier 1 | 0.684 | 1 | A_assoc | 1 | 75.44 | 0 | 0 | 1 | 3 | 38155321, 24146916, 23918801 | 0 | heterotaxy, visceral, 5, autosomal | 0.7788051667024423 | ||
| Q9UKJ1 | PILRA | Paired immunoglobulin-like type 2 receptor alpha | Tier 1 | 0.684 | 1 | A_surface | 6 | 69.5 | 0 | 0 | 1 | 1 | 34819519 | 0 | Alzheimer disease | 0.44504475030909274 | ||
| Q86XE3 | MICU3 | Calcium uptake protein 3, mitochondrial | Tier 1.5 | 0.684 | 1 | A_surface | 2 | 71.25 | 0 | 0 | 1 | 1 | 26318819 | 0 | neurodegenerative disease | 0.4480613767359447 | ||
| P01138 | NGF | Beta-nerve growth factor | Tier 1.5 | 0.684 | 1 | A_assoc | 8 | 73.25 | 0 | 0 | 1 | 6 | 42015870, 38780008, 32982626, 21216401, 7545283, 29754498 | 0 | hereditary sensory and autonomic neuropathy type 5 | 0.7785402119369383 | ||
| P18510 | IL1RN | Interleukin-1 receptor antagonist protein | Tier 1.5 | 0.682 | 1 | A_assoc | 5 | 87.06 | 0 | 0 | 1 | 1 | 38928037 | 0 | sterile multifocal osteomyelitis with periostitis and pustulosis | 0.7734282711738736 | ||
| P00797 | REN | Renin | Tier 1 | 0.68 | 1 | A_assoc | 91 | 85.44 | 0 | 0 | 1 | 456 | 42025056, 42000159, 41992303, 41979049, 41942404, 41934998, 41909751, 41904852, 41851110, 41849890, 41794534, 41780402, 41770936, 41718462, 41711853, 41698160, 41671930, 41659919, 41629318, 41545413, 41538945, 41529264, 41519163, 41454539, 41443106, 41386094, 41330678, 41327249, 41249026, 41234744, 41207040, 41205456, 41175848, 41172349, 41171135, 41164194, 41161441, 41148632, 41118515, 41089000, 41067030, 41024479, 41002305, 40994449, 40968863, 40963922, 40893365, 40891676, 40870790, 40801503, 41906877, 40832436, 39923730, 39263947, 39129649, 38811951, 36190914, 35983901, 35907639, 35187107, 34619249, 34248841, 32981365, 32838280, 32527800, 31988066, 26746799, 21147843 | 0 | familial juvenile hyperuricemic nephropathy type 2 | 0.7657976389758877 | ||
| Q9BQ51 | PDCD1LG2 | Programmed cell death 1 ligand 2 | Tier 1.5 | 0.678 | 1 | A_surface | 2 | 86.38 | 0 | 0 | 1 | 1 | 38928037 | 0 | melanoma | 0.42716921377769757 | ||
| Q8TD46 | CD200R1 | Cell surface glycoprotein CD200 receptor 1 | Tier 1.5 | 0.676 | 1 | A_surface | 1 | 74.56 | 0 | 0 | 1 | 4 | 35359946, 31811336, 30195773, 25158092 | 0 | atopic eczema | 0.4186418842135947 |
Advanced export
JSON shape: default, array, newline-delimited
CREATE VIEW v_targets AS
SELECT f.id, n.gene_symbol, n.protein_name, tg.tier,
-- evidence_priority: DETERMINISTIC, reproducible from real DB columns (no LLM).
-- Transparent weights over harvested evidence: structure 0.35, disease importance
-- 0.30 (Open Targets top-disease score), PREDICTED surface accessibility 0.20,
-- EV detection 0.15. A heuristic ranking aid, not a validation; surface/EV terms
-- are predictions/detections, NOT measured EV-surface exposure.
ROUND(
0.35*(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1.0
WHEN CAST(COALESCE(NULLIF(f.alphafold_mean_pLDDT,''),'0') AS REAL)>0 THEN 0.3 ELSE 0.0 END)
+ 0.30*MIN(CAST(COALESCE(NULLIF(f.opentargets_top_disease_score,''),'0') AS REAL), 1.0)
+ 0.20*(CASE sc.surface_class WHEN 'A_surface' THEN 1.0 WHEN 'A_assoc' THEN 0.5 WHEN 'A2_pm_peripheral' THEN 0.2 ELSE 0.0 END)
+ 0.15*(CASE WHEN CAST(COALESCE(f.in_cev_map,0) AS INTEGER)=1 THEN 1.0 ELSE 0.0 END)
, 3) AS evidence_priority,
(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1 ELSE 0 END) AS has_structure,
sc.surface_class,
f.pdb_count_total, f.alphafold_mean_pLDDT, f.has_cryoEM,
f.has_activation_state_pdb_pair, f.activation_state_pdb_active, f.activation_state_pdb_inactive,
f.has_known_aptamer, f.aptamer_count_pubmed, ap.aptamer_pmids,
f.in_cev_map, f.opentargets_top_disease_name, f.opentargets_top_disease_score
FROM v_target_full f
LEFT JOIN target_names n ON n.target_id=f.id
LEFT JOIN targets tg ON tg.id=f.id
LEFT JOIN target_aptamer_pmids ap ON ap.target_id=f.id
LEFT JOIN membrane_surface_class sc ON sc.target_id=f.id;